Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.6 - $2.82 $36,867 - $64,978
23,042 Added 61.34%
60,604 $118,000
Q4 2022

Feb 14, 2023

BUY
$1.11 - $1.64 $41,693 - $61,601
37,562 New
37,562 $58,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $323M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.